AAV

Overcoming Variability and Scaling Challenges in AAV Manufacturing

Rafal Garus

Viralgen Vector Core

Synthetic DNA

Transforming the Economics of AAV Manufacture While Optimizing Quality with dbDNA

Tom Merritt, Ph.D.

Touchlight

Viral Vectors

Facing the Dual Scientific and Financial Challenges to Advance Cell and Gene Therapies

Jimmy Vanhove

Viralgen Vector Core

AAV Capsid Engineering

Expanding Patient Access to Gene Therapies through AAV Capsid Engineering

Damien Marsic, Ph.D.

Porton Advanced Solutions

Gene Therapy Analytics

Overcoming Analytical Challenges for Gene Therapies

Jennifer Chadwick, Ph.D.

ProtaGene

Gene Therapy

Beyond 2020: Looking into the Crystal Ball for Gene Therapy

Ratish Krishnan

MilliporeSigma

AAV Platform Technologies

Increasing Predictability with AAV Platform Technologies

Felix Hsu

WuXi Advanced Therapies

Depth Filtration

Robust Harvest Clarification for Adeno-Associated Viral Vectors via Depth Filtration

Youness Cherradi, Ph.D.; Thomas Parker; Claire Scanlan; Elina Gousseinov

MilliporeSigma

AAV Vector Production

Challenges to Process Validation for Viral Vectors

Kyle Zingaro, Ph.D.; Deborah Mar Begos; Todd Miller

Thermo Fisher Scientific

AAV

WuXi Advanced Therapies Launches New World-Class AAV Vector Suspension Platform

WuXi Advanced Therapies (WAT)

CDMO

Yposkesi Selected to Produce Clinical and Large-Scale Commercial Material of Micro-Dystrophin for Genethon and Sarepta Therapeutics Program

Yposkesi

Plasmids

The Pivotal Role of Plasmid DNA

Robert Reames

Aldevron

AAV Vector Production

Production of AAV Vectors Using Suspension Mammalian and Insect Cell Systems

Richard Snyder, Ph.D.; Jessica Tate, Ph.D.; Hetal Brahmbhatt, Ph.D.; Steven G. Milian, M.S.

Thermo Fisher Scientific